Introduction: The main cause of hyperthyroidism in the world is Graves' disease and its incidence is rising. In Colombia, the epidemiology of Graves’ disease has been assumed to be like that of other countries with iodine sufficiency. In other regions, differences have been reported between specialists in the diagnosis and treatment of Graves' disease.
Purpose: A national survey was conducted based on hypothetical clinical cases to know the decisions of Colombian endocrinologists in the treatment of Graves' disease.
Methodology: Survey based on a web management service applied to specialists in endocrinology members of the Colombian Association of Endocrinology. The percentage of responses was obtained individually for each question, using the number of respondents in the denominator.
Results: Of the contacted endocrinologist 36% answered the survey. At the time of diagnosis most would repeat the measurement of TSH and free T4 (83% and 81%, respectively). 61% would request a thyroid scan with technetium. Most of the respondents would use beta blockers associated with an antithyroid as the first line of treatment and in all cases the selected antithyroid was methimazole. A significant proportion of respondents would follow up with a blood count or liver function tests besides than thyroid function tests. A non-negligible number of patients would be treated by their physician with antithyroid for a period of less than one year.
Conclusions: This study suggests the current treatment state of Graves' Disease in Colombia by specialists in endocrinology, which in most aspects follow the recommendations of the guidelines published in other countries. Some behaviors are far from evidence-based recommendations and this could expose patients with Graves' disease to unnecessary risks or impose additional costs to the healthcare system. Some of the reported practices are influenced by conditions of the Colombian health system or availability, which suggests that local guides adapted to these peculiarities should be developed.
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016 ag. 27;388(10047):906-18. https://doi.org/10.1016/S0140-6736(16)00278-6
Garmendia-Madariaga A, Santos-Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014;99(3):923-31. https://doi.org/10.1210/jc.2013-2409
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-99. https://doi.org/10.1210/jcem.87.2.8182
Abraham-Nordling M, Byström K, Törring O, Lantz M, Berg G, Calissendorff J, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011;165(6):899-905. https://doi.org/10.1530/EJE-11-0548
Ardila E, Escobar ID, Páez A, Arteaga JM, De Bernal M, Castro G. Consenso colombiano para el diagnóstico y manejo de las enfermedades tiroideas. Acta Med Colomb. 1999;24(4):19.
Bahn-Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593-646. https://doi.org/10.1089/thy.2010.0417
Kahaly GJ, Bartalena L, Hegedüs L. The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid. 2011;21(6):585-91. https://doi.org/10.1089/thy.2011.2106.ed3
Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab. 2012;97(12):4549-58. https://doi.org/10.1210/jc.2012-2802
Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol (Oxf). 2016;84(1):115-20. https://doi.org/10.1111/cen.12688
Negro R, Attanasio R, Grimaldi F, Guglielmi R, Papini E. A 2015 Italian Survey of Clinical Practice Patterns in the Management of Graves' Disease: Comparison with European and North American Surveys. Eur Thyroid J. 2016;5(2):112-9. https://doi.org/10.1159/000444482
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-421. https://doi.org/10.1089/thy.2016.0229
Barbesino G, Tomer Y. Clinical review: Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab. 2013;98(6):2247-55. https://doi.org/10.1210/jc.2012-4309
Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab. 2010;95(5):2227-33. https://doi.org/10.1210/jc.2009-2752
Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, Kami M, et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease. J Clin Endocrinol Metab. 2012;97(1):E49-53. https://doi.org/10.1210/jc.2011-2221
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2021 Revista Endocrino